Bionic eye transplant proves to be a success: what does that mean for surgical technology?

By Admin
Written by Alyssa Clark The University of Michigans Health System surgeons have successfully made the first FDA-approved “bionic eye” tran...

Written by Alyssa Clark

 

The University of Michigan’s Health System surgeons have successfully made the first FDA-approved “bionic eye” transplants; not only does this new technology allow patients with degenerative eye disease to see again, but they are reinstated with a range of normal vision capabilities like making out lights and shapes. The Michigan Daily reported, “on January 16th and 22nd, two surgeons successfully implanted the Argus II artificial retina, which is composed of a sheet of electrodes fixed to the eye. The implant is paired with a pair of camera-equipped glasses and a processor that captures video from the glasses. That video is then sent as a series of pulses to the electrodes, stimulating the patient's remaining nerve fibers.”

The eye had already been tested by approximately 50 people worldwide when it was finally approved by the FDA early on in 2013. Second Sight, Argus’s developer has designated 12 centers including UMHS to conduct the procedure on a wider range of patients.

The Argus II does not give the patients full, normal range of vision; however, it gives the patient the ability to access normal vision responses, like seeing flashes of light and being able to learn/read visual patterns. Two of the surgeons who conducted the implant have already begun to discuss the future of the technology, and the impact it is set to have on the medical technology market.

“That process of learning takes between one to three months”, says Thiran Jayasundera, one of the surgeons who transplanted the retina. “It's far from perfect, but it restores some sight to people suffering from retinitis pigmentosa, a hereditary condition that causes degraded sight and, ultimately, blindness. It's possible to slow the condition's progress, but something like the Argus II is needed to actually restore vision.”

The verge has reported that, “In Europe, officials have also approved a second artificial retina: the higher-resolution Alpha IMS, which requires no glasses and allows more freedom of movement, since users can simply look around instead of turning their head to capture video. A pre-approval pilot program saw the Alpha IMS successfully implanted in eight patients and unsuccessfully implanted in one.”

Share
Share

Featured Articles

Philip Morris International (PMI) in agreement with KT&G

PMI and KT&G are building a smoke-free world. In a new agreement between the two companies, smoke-free alternatives are within reach for smokers

Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Automating gene therapy & pharma discovery at Automata

Sonia Jassi, Drug Discovery & Synthetic Biology Lead at Automata, explains how automation increases efficiency in gene therapy laboratories

Itai Hayut, CEO of Scopio Labs, on AI & blood cancer

Technology & AI

2023 predictions with Harshit Jain, global CEO of Doceree

Telehealth & COVID-19

Wolters Kluwer Health: health equity and telehealth

Telehealth & COVID-19